Identification of a biomarker to predict doxorubicin/cisplatin chemotherapy efficacy in osteosarcoma patients using primary, recurrent and metastatic specimens

MLA

Qiong Ma, et al. “Identification of a Biomarker to Predict Doxorubicin/Cisplatin Chemotherapy Efficacy in Osteosarcoma Patients Using Primary, Recurrent and Metastatic Specimens.” Translational Oncology, vol. 49, no. 102098-, Nov. 2024. EBSCOhost, https://doi.org/10.1016/j.tranon.2024.102098.

APA

Qiong Ma, Jin Sun, Qiao Liu, Jin Fu, Yanhua Wen, Fuqin Zhang, Yonghong Wu, Xiaoyu Zhang, Li Gong, & Wei Zhang. (2024). Identification of a biomarker to predict doxorubicin/cisplatin chemotherapy efficacy in osteosarcoma patients using primary, recurrent and metastatic specimens. Translational Oncology, 49(102098-). https://doi.org/10.1016/j.tranon.2024.102098

Chicago

Qiong Ma, Jin Sun, Qiao Liu, Jin Fu, Yanhua Wen, Fuqin Zhang, Yonghong Wu, Xiaoyu Zhang, Li Gong, and Wei Zhang. 2024. “Identification of a Biomarker to Predict Doxorubicin/Cisplatin Chemotherapy Efficacy in Osteosarcoma Patients Using Primary, Recurrent and Metastatic Specimens.” Translational Oncology 49 (102098-). doi:10.1016/j.tranon.2024.102098.